Lawmakers released annual defense authorization legislation that backs almost $901 billion in discretionary spending for national security programs and seeks to restrict American investments in sensitive Chinese industries.
Congressional leaders also included legislation that would bar certain Chinese biotech companies from receiving federal funding, according to senior House Republican leadership aides who spoke on condition of anonymity to discuss bill details. Last year’s version of the funding restrictions, dubbed the Biosecure Act, was omitted from the final defense policy bill over some lawmakers’ concerns about naming specific companies.
The National Defense Authorization Act is considered one of the few must-pass ...